[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, Hwu P, Tannir NM: Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer; 2009 Jan;7(1):20-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.
  • BACKGROUND: Sorafenib-induced dermatologic toxicity is common and consists primarily of dry skin, maculopapular rash, hand-foot skin reaction, and alopecia.
  • Cutaneous squamous cell carcinoma (SCC) and inflammation of actinic keratosis (AK) were reported in 2 patients treated with sorafenib (Lacouture et al), but the scope of this observation has not been evaluated.
  • PATIENTS AND METHODS: We reviewed medical records of 131 patients with metastatic renal cell carcinoma treated with single-agent sorafenib at our institution from June 1, 2005, through April 4, 2007.
  • RESULTS: We identified 7 cases of cutaneous SCC, 2 cases of SCC keratoacanthoma type, 2 cases of focal squamous atypia, and 3 cases of AKs.
  • The time to development of SCC or AK from the start of sorafenib was 9.3 months (median, 6.5 months; range, 0.9-43 months).
  • Ten of these 14 patients discontinued therapy with sorafenib: 7 patients as a result of disease progression, 2 patients as a result of nondermatologic toxicity, and 1 patient as a result of dermatologic toxicity.
  • Four patients are continuing sorafenib therapy at reduced doses because of diarrhea and fatigue.
  • One patient receiving sorafenib at a 25% dose reduction developed a second invasive SCC lesion on his forearm 6 months after the initial resection.
  • CONCLUSION: These data suggest that there could be an association between sorafenib therapy and the development of cutaneous SCC and inflammation of AK.
  • This adverse event has important therapeutic implications.
  • [MeSH-major] Benzenesulfonates / adverse effects. Carcinoma, Squamous Cell / chemically induced. Drug Eruptions / etiology. Keratosis, Actinic / chemically induced. Protein Kinase Inhibitors / adverse effects. Pyridines / adverse effects. Skin Neoplasms / chemically induced
  • [MeSH-minor] Aged. Carcinoma, Renal Cell / drug therapy. Female. Humans. Inflammation / chemically induced. Inflammation / pathology. Keratoacanthoma / chemically induced. Keratoacanthoma / pathology. Kidney Neoplasms / drug therapy. Male. Middle Aged. Niacinamide / analogs & derivatives. Phenylurea Compounds

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Genitourin Cancer. 2009 Jan;7(1):9-10 [19213661.001]
  • (PMID = 19213663.001).
  • [ISSN] 1558-7673
  • [Journal-full-title] Clinical genitourinary cancer
  • [ISO-abbreviation] Clin Genitourin Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  • [Other-IDs] NLM/ NIHMS773866; NLM/ PMC4825856
  •  go-up   go-down


2. Han JY, Lee DH, Lee SY, Park CG, Kim HY, Lee HG, Lee JJ, Kim HT, Lee JS: Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma. Cancer; 2005 Dec 15;104(12):2759-65
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma.
  • BACKGROUND: A Phase II study was conducted to evaluate the efficacy and toxicity of an irinotecan plus capecitabine combination, a new nonplatinum regimen, in chemonaive patients with advanced nonsmall cell lung carcinoma (NSCLC).
  • METHODS: Between July 2003 and April 2004, 53 patients with a histologically confirmed diagnosis of NSCLC were enrolled.
  • Treatment consisted of intravenous irinotecan at a dose of 90 mg/m(2) on Days 1 and 8 and oral capecitabine at a dose of 1000 mg/m(2) twice daily on Days 1-14 of each 21-day cycle, given up to 12 cycles.
  • Treatment was very well tolerated, with only 10% of patients experiencing NCI-CTC Grade 3 or 4 toxicities.
  • The most common toxicities were hand-foot syndrome and diarrhea.
  • Squamous cell carcinoma was marginally predictive for better response (P = 0.08).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Fluorouracil / analogs & derivatives. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Staging. Probability. Prognosis. Risk Assessment. Statistics, Nonparametric. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16294344.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


3. Hitt R, Jimeno A, Rodríguez-Pinilla M, Rodríguez-Peralto JL, Millán JM, López-Martín A, Brandariz A, Peña C, Cortés-Funes H: Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors. Br J Cancer; 2004 Dec 13;91(12):2005-11
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors.
  • The combination of cisplatin and capecitabine was evaluated in patients with recurrent or unresectable squamous cell carcinoma of the head and neck (HNSCC), and outcome parameters were correlated with the expression of thymidine phosphorylase (TP), thymidilate syntetase (TS), vascular endothelial growth factor receptor (VEGFR) 1-3, and microvessel density (MVD).
  • Patients with recurrent or unresectable HNSCC were eligible if they had received prior neoadjuvant chemotherapy, concurrent chemo-radiotherapy, or no prior systemic therapy.
  • Asthenia, anorexia, hand-foot syndrome, and constipation were the most frequent nonhaematologic events.
  • [MeSH-major] Angiogenesis Inducing Agents / metabolism. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Cisplatin / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Capecitabine. Fluorouracil / analogs & derivatives. Humans. Immunohistochemistry. Male. Middle Aged. Receptors, Vascular Endothelial Growth Factor / biosynthesis. Thymidine Phosphorylase / biosynthesis. Thymidylate Synthase / biosynthesis. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Biol Chem. 1964 Aug;239:2618-21 [14235544.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6298-302 [11103787.001]
  • [Cites] Pathol Int. 2001 Mar;51(3):158-64 [11328530.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):556-68 [11505400.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2B):1039-44 [12168898.001]
  • [Cites] Ann Surg. 2002 Dec;236(6):738-49; discussion 749 [12454512.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1578-86 [14504061.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1983 Jan;31(1):175-8 [6221809.001]
  • [Cites] J Clin Oncol. 1985 Aug;3(8):1105-8 [4040550.001]
  • [Cites] Acta Otolaryngol. 1987 May-Jun;103(5-6):519-28 [3303823.001]
  • [Cites] Biometrics. 1989 Jun;45(2):537-47 [2765637.001]
  • [Cites] J Clin Oncol. 1992 Feb;10(2):257-63 [1732427.001]
  • [Cites] J Clin Oncol. 1992 Aug;10(8):1245-51 [1634913.001]
  • [Cites] J Natl Cancer Inst. 1993 Jan 20;85(2):95-111 [8418313.001]
  • [Cites] J Natl Cancer Inst. 1994 Feb 16;86(4):250-2 [8158674.001]
  • [Cites] Ann Oncol. 1994 Jul;5(6):521-6 [7522527.001]
  • [Cites] Semin Surg Oncol. 1995 May-Jun;11(3):265-71 [7638514.001]
  • [Cites] Eur J Cancer. 1996 Jun;32A(7):1227-32 [8758258.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):110-5 [8996131.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3223-9 [9336359.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):685-90 [9485021.001]
  • [Cites] Biochem Pharmacol. 1998 Apr 1;55(7):1091-7 [9605432.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):381-9 [10690514.001]
  • (PMID = 15597103.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 2.1.1.45 / Thymidylate Synthase; EC 2.4.2.4 / Thymidine Phosphorylase; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2409797
  •  go-up   go-down


Advertisement
4. Sheen YS, Sheen MC, Sheu HM, Yang SF, Wang YW: Squamous cell carcinoma of the big toe successfully treated by intra-arterial infusion with methotrexate. Dermatol Surg; 2003 Sep;29(9):982-3
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the big toe successfully treated by intra-arterial infusion with methotrexate.
  • BACKGROUND: For preservation of integrity of appearance and function in a 57-year-old male with a squamous cell carcinoma of his left big toe who had refused amputation, intra-arterial infusion with methotrexate was used.
  • RESULTS: At 7 years and 3 months after therapy, the patient was in sustained complete remission with a functionally normal left foot.
  • CONCLUSION: This case study suggests that intra-arterial infusion chemotherapy is a simple and effective method for big toe squamous cell carcinoma with the unique advantage of preservation of organ and function.
  • It can be considered as an effective alternative treatment.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Methotrexate / administration & dosage. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12930347.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


5. Verschraegen CF, Kavanagh JJ, Loyer E, Bodurka-Bevers D, Kudelka AP, Hu W, Vincent M, Nelson T, Levenback C, Community Clinical Oncology Program: Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix. Cancer; 2001 Nov 1;92(9):2327-33
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix.
  • BACKGROUND: The activity of the combination of carboplatin and liposomal doxorubicin was tested in a Phase II study of patients with recurrent cervical carcinoma.
  • METHODS: The combination of carboplatin (area under the concentration curve [AUC], 5) and liposomal doxorubicin (Doxil; starting dose, 40 mg/m(2)) was administered intravenously every 28 days to 37 patients with recurrent squamous cell cervical carcinoma to determine antitumor activity and toxicity profile.
  • The overall response rate was 38%, the median time to response was 10 weeks, the median duration of response was 26 weeks, and the median survival was 37 weeks.
  • Four patients had five infusion-related reactions during the infusion of liposomal doxorubicin, leading to treatment discontinuation in three patients.
  • Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients.
  • CONCLUSIONS: The combination of carboplatin and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Neoplasm Recurrence, Local / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Anemia / chemically induced. Carboplatin / administration & dosage. Carboplatin / adverse effects. Disease Progression. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Infusions, Intravenous. Liposomes. Middle Aged. Neutropenia / chemically induced. Thrombocytopenia / chemically induced. Treatment Outcome


6. Lee J, Im YH, Cho EY, Hong YS, Lee HR, Kim HS, Kim MJ, Kim K, Kang WK, Park K, Shim YM: A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol; 2008 Jun;62(1):77-84
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
  • PURPOSE: The combination of 5-fluorouracil (5-FU) and cisplatin (FP) remains the mostly used regimen for metastatic esophageal squamous carcinoma.
  • This phase II study assessed the efficacy and safety of capecitabine/cisplatin (XP) as a first-line chemotherapy in a homogenous cohort of patients with metastatic or recurrent esophageal squamous cell carcinoma.
  • Treatment cycles were repeated every 3 weeks until the documented disease progression, unacceptable toxicity, or patient's refusal.
  • Immunohistochemical studies against thymidylate synthase (TS) and thymidine phosphorylase (TP) were performed to seek predictive markers for treatment response.
  • All patients had histologically proven squamous cell carcinoma of the esophagus.
  • With a median follow-up duration of 25.7 months (10.8-42.6 months), the median time to progression was 4.7 months (95% CI, 2.5-7.0) and the median survival time was 11.2 months (95% CI, 8.5-13.9).
  • Common grade 3 or 4 non-hematological adverse events were anorexia (18/191, 9.4%), fatigue (9/191, 4.7%), constipation (6/191, 3.1%), hand-foot syndrome (6/191, 3.1%) and diarrhea (4/191, 2.1%).
  • There was no treatment-related death.
  • Neither TS nor TP showed predictive value for treatment response.
  • CONCLUSION: The XP regimen demonstrated a promising antitumor activity in metastatic esophageal squamous cell carcinoma, which may potentially replace the FP regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762932.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 2.1.1.45 / Thymidylate Synthase; EC 2.4.2.4 / Thymidine Phosphorylase; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Williamson SK, Moon J, Huang CH, Guaglianone PP, LeBlanc M, Wolf GT, Urba SG: Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J Clin Oncol; 2010 Jul 10;28(20):3330-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.
  • PURPOSE: We conducted a phase II trial to evaluate the efficacy and safety of single-agent sorafenib in chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN).
  • PATIENTS AND METHODS: Chemotherapy-naïve patients with metastatic, persistent, or recurrent SCCHN who received one induction or fewer or received an adjuvant chemotherapy regimen, who had adequate organ function, and who had a performance status <or= 1 were eligible.
  • The most common grades 2 to 3 adverse events were fatigue, anorexia, stomatitis/oral pain, abdominal pain, hand-foot syndrome, weight loss, and hypertension.
  • Although response was poor, progression-free and overall survival times compare favorably with previous Southwest Oncology Group, phase II, single-agent trials.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Pyridines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Drug Evaluation. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Niacinamide / analogs & derivatives. Phenylurea Compounds

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Curr Opin Oncol. 2009 May;21(3):206-11 [19346943.001]
  • [Cites] Invest New Drugs. 2001;19(4):311-5 [11561690.001]
  • [Cites] Laryngoscope. 2001 Oct;111(10):1834-41 [11801954.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18 Suppl):1S-13S [12235219.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7154-6 [12499248.001]
  • [Cites] Int J Clin Pharmacol Ther. 2002 Dec;40(12):580-1 [12503822.001]
  • [Cites] Cell Signal. 2003 May;15(5):463-9 [12639709.001]
  • [Cites] Head Neck. 2003 Jun;25(6):464-74 [12784238.001]
  • [Cites] Int J Clin Pharmacol Ther. 2003 Dec;41(12):616-7 [14692718.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] J Clin Oncol. 1992 Aug;10(8):1245-51 [1634913.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 [7612182.001]
  • [Cites] Invest New Drugs. 1996;14(4):403-7 [9157077.001]
  • [Cites] FEBS Lett. 1997 Jun 23;410(1):83-6 [9247128.001]
  • [Cites] Adv Cancer Res. 1998;74:49-139 [9561267.001]
  • [Cites] Oncogene. 1998 Sep 17;17(11 Reviews):1395-413 [9779987.001]
  • [Cites] Invest New Drugs. 1998-1999;16(3):271-4 [10360608.001]
  • [Cites] Anticancer Drugs. 2005 Feb;16(2):129-36 [15655409.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):965-72 [15613696.001]
  • [Cites] Int J Exp Pathol. 2005 Dec;86(6):347-63 [16309541.001]
  • [Cites] Cancer. 2006 Jul 15;107(2):319-27 [16779801.001]
  • [Cites] Mol Cancer Ther. 2006 Sep;5(9):2378-87 [16985072.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Dec;319(3):1070-80 [16959960.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Cancer Invest. 2007 Apr-May;25(3):182-8 [17530488.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2171-7 [17538161.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3766-73 [17704426.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9443-54 [17909054.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1088-95 [11181673.001]
  • (PMID = 20498388.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA35128; United States / NCI NIH HHS / CA / N01 CA035431; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / U10 CA035128; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / U10 CA045808; United States / NCI NIH HHS / CA / CA58658; United States / NCI NIH HHS / CA / N01 CA045807; United States / NCI NIH HHS / CA / N01 CA035119; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / N01 CA046441; United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA16385; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / U10 CA067575; United States / NCI NIH HHS / CA / U10 CA046441; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / CA76448; United States / NCI NIH HHS / CA / U10 CA042777; United States / NCI NIH HHS / CA / U10 CA035431; United States / NCI NIH HHS / CA / U10 CA035119; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / U10 CA011083; United States / NCI NIH HHS / CA / CA52654; United States / NCI NIH HHS / CA / N01 CA067575; United States / NCI NIH HHS / CA / U10 CA052654; United States / NCI NIH HHS / CA / U10 CA035090; United States / NCI NIH HHS / CA / U10 CA045807
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  • [Other-IDs] NLM/ PMC2903329
  •  go-up   go-down


8. Qin TJ, An GL, Zhao XH, Tian F, Li XH, Lian JW, Pan BR, Gu SZ: Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer. World J Gastroenterol; 2009 Feb 21;15(7):871-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer.
  • AIM: To investigate the efficacy and side effects of the combined therapy of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer (ESCC) and the survival of the patients.
  • METHODS: Sixty-four patients (median age of 63 years) with histological or cytological confirmation of ESCC received oxaliplatin 120 mg/m(2) intravenously on day 1 and capecitabine 1000 mg/m(2) orally twice daily on days 1 to 14 in a 21-d treatment cycle as palliative chemotherapy.
  • Each patient received at least two cycles of treatment.
  • The main toxicities were leukopenia (50.0%), nausea and vomiting (51.6%), diarrhea (50.0%), stomatitis (39.1%), polyneuropathy (37.5%) and hand-foot syndrome (37.5%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Leukopenia / chemically induced. Life Tables. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Palliative Care. Patient Selection. Prognosis. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2002 Jul;38(11):1495-500 [12110496.001]
  • [Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 2008 Jan;29(1):44-7 [18785477.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2129-33 [15942631.001]
  • [Cites] Ann Oncol. 2005 Aug;16(8):1320-5 [15919687.001]
  • [Cites] Am J Clin Oncol. 2005 Aug;28(4):329-33 [16062072.001]
  • [Cites] Cancer Detect Prev. 2005;29(4):317-22 [16118042.001]
  • [Cites] Ann Oncol. 2006 Jan;17(1):29-34 [16303863.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2006 Mar;28(3):230-4 [16875614.001]
  • [Cites] Br J Cancer. 2007 May 7;96(9):1348-52 [17437008.001]
  • [Cites] Environ Int. 2007 Jul;33(5):603-8 [17267034.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4C):2705-14 [17695436.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4C):2845-8 [17695458.001]
  • [Cites] Am J Clin Oncol. 2007 Aug;30(4):346-9 [17762433.001]
  • [Cites] Anticancer Drugs. 2007 Jul;18(6):703-8 [17762400.001]
  • [Cites] Cancer Invest. 2007 Sep;25(6):445-8 [17882656.001]
  • [Cites] Jpn J Clin Oncol. 2007 Nov;37(11):829-35 [17951334.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2007;21(6):921-45 [18070696.001]
  • [Cites] Sci Total Environ. 2008 Apr 15;393(2-3):219-25 [18243281.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Jun;62(1):77-84 [17762932.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1965; author reply 1965 [18450611.001]
  • [Cites] Cancer. 2008 May 15;112(10):2166-72 [18348303.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2004 Dec;26(12):753-5 [15733398.001]
  • (PMID = 19230050.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2653389
  •  go-up   go-down


9. Jenkins AD, Ramondetta LM, Sun C, Johnston T, Wolf JK, Bodurka DC, Brown J, Atkinson EN, Levenback C: Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix. Gynecol Oncol; 2005 Jun;97(3):840-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix.
  • PURPOSE: To determine the efficacy and safety of capecitabine in women with inoperable, recurrent, or metastatic squamous cell cervical cancer.
  • Quality of life data were obtained using the Memorial Symptom Assessment Scale and Functional Assessment for Cancer Therapy, which included a subscale for cervical cancer.
  • Common grade 3 toxicities were fatigue (30.4%); abdominal pain, constipation, hand-foot syndrome, nausea, and vomiting (8.7% each); as well as dyspnea, headache, and coagulopathy (4.3% each).
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Capecitabine. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Fluorouracil / analogs & derivatives. Humans. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15882895.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abrão Miziara JE, Balint B, De Marinis F, Keller A, Arén O, Csollak M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, Dimatteo S, Hanna N: Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol; 2010 Apr 10;28(11):1835-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
  • PURPOSE This phase III, multicenter, randomized, placebo-controlled trial assessed the efficacy and safety of sorafenib, an oral multikinase inhibitor, in combination with carboplatin and paclitaxel in chemotherapy-naïve patients with unresectable stage IIIB or IV non-small-cell lung cancer (NSCLC).
  • RESULTS Overall demographics were balanced between arms; 223 patients (24%) had squamous cell histology.
  • A prespecified exploratory analysis revealed that patients with squamous cell histology had greater mortality in arm A than in arm B (HR = 1.85; 95% CI, 1.22 to 2.81).
  • Main grade 3 or 4 sorafenib-related toxicities included rash (8.4%), hand-foot skin reaction (7.8%), and diarrhea (3.5%).
  • CONCLUSION No clinical benefit was observed from adding sorafenib to CP chemotherapy as first-line treatment for NSCLC.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Large Cell / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Squamous Cell / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Benzenesulfonates / administration & dosage. Carboplatin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Niacinamide / analogs & derivatives. Paclitaxel / administration & dosage. Phenylurea Compounds. Placebos. Pyridines / administration & dosage. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2010 Apr 10;28(11):1810-2 [20212244.001]
  • (PMID = 20212250.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Placebos; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


11. Wirth LJ, Haddad RI, Wieczorek TJ, Faucher JL, Clark JR, Norris CM, Posner MR: Phase I study of gefitinib plus celecoxib in patients with metastatic and/or locally recurrent squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol; 2004 Jul 15;22(14_suppl):5540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of gefitinib plus celecoxib in patients with metastatic and/or locally recurrent squamous cell carcinoma of the head and neck (SCCHN).
  • : 5540 Background: Treatment options for incurable metastatic and/or locally recurrent SCCHN are limited.
  • Platinum-based therapy yields response rates of approximately 30%, and median survival of 6-7 months.
  • Eligible patients had measurable metastatic and/or locally recurrent SCCHN, at least 1 prior chemotherapy, performance status 2 or better, and adequate end-organ function.
  • The most common toxicities were rash (predominately acneiform), diarrhea and hand-foot syndrome (HFS).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013989.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Domingo E, Lorvidhaya V, de Los Reyes R, Syortin T, Kamnerdsupaphon P, Lertbutsayanukul C, Vito-Cruz E, Tharavichitkul E, Jin K, Yoshihara M, Cupino N, Lertsanguansinchai P: Capecitabine-based chemoradiotherapy with adjuvant capecitabine for locally advanced squamous carcinoma of the uterine cervix: phase II results. Oncologist; 2009 Aug;14(8):828-34
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine-based chemoradiotherapy with adjuvant capecitabine for locally advanced squamous carcinoma of the uterine cervix: phase II results.
  • OBJECTIVES: Cisplatin-based chemoradiotherapy is the standard treatment for locally advanced cervical cancer but causes considerable toxicity.
  • The activity, tolerability, and oral administration of capecitabine make it an attractive adjunctive therapy.
  • METHODS: In this phase II study, patients with untreated International Federation of Gynecology and Obstetrics stage IIB-IIIB cervical cancer received capecitabine, 825 mg/m(2) twice daily (Monday-Friday), during radiation (45 Gy per 25 fractions external-beam radiotherapy and 26 Gy high-dose rate brachytherapy to point A, maximum 8 weeks), followed by six cycles of capecitabine, 1,000 mg/m(2) twice daily (days 1-14 every 21 days).
  • There were three grade 3 or 4 treatment-related events: reversible grade 4 hypokalemia, grade 3 diarrhea, and grade 3 hand-foot syndrome.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Brachytherapy. Capecitabine. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661184.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Voutsadakis IA, Bruckner HW: Eccrine sweat gland carcinoma: a case report and review of diagnosis and treatment. Conn Med; 2000 May;64(5):263-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eccrine sweat gland carcinoma: a case report and review of diagnosis and treatment.
  • Carcinomas of the skin appendices are rare neoplasms but for prognostic reasons it is important to differentiate them from the indolent squamous and basal cell carcinomas, as their behavior is more aggressive.
  • We report on a case of eccrine sweat gland carcinoma that displayed all the typical features of those neoplasms.
  • The patient sought medical attention after a lesion in his foot, already present for four years, began to enlarge and developed satellite lesions.
  • The pathological diagnosis was made only after the lesion was initially misdiagnosed as basal cell carcinoma of the skin.
  • Multiple chemotherapeutic regimens and radiation therapy were administered with only temporary benefit.
  • The patient developed distant metastatic disease but survived with metastases for three years.
  • He died nine years after the initial lesion developed in his foot and five years after the diagnosis.
  • The diagnosis of sweat gland carcinomas can be facilitated by histochemical stains.
  • In contrast to squamous and basal cell carcinomas of the skin, these are generally positive for the carcinoembryonic antigen (CEA).
  • Once metastatic, these neoplasms are only infrequently, and usually briefly, responsive to either chemotherapy or radiotherapy and new treatments are urgently needed.
  • Early recognition of the entity may allow more timely treatment.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / therapy. Sweat Gland Neoplasms / diagnosis. Sweat Gland Neoplasms / pathology. Sweat Gland Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Fatal Outcome. Humans. Leg. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Radiotherapy, Adjuvant. Skin Neoplasms / diagnosis. Spinal Neoplasms / secondary. Thoracic Vertebrae

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10860232.001).
  • [ISSN] 0010-6178
  • [Journal-full-title] Connecticut medicine
  • [ISO-abbreviation] Conn Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 31
  •  go-up   go-down


14. Kuruvila S, Dalal M, Sivanesan B: Bullous variant of acral erythema due to methotrexate. Indian J Dermatol Venereol Leprol; 2006 Nov-Dec;72(6):440-2
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chemotherapy-induced acral erythema is a painful erythema of the palms and soles which occurs following chemotherapy.
  • We present a 40-year-old male patient, a biopsy proven case of squamous cell carcinoma of the floor of the mouth, who developed a bullous variant of acral erythema after a single intravenous dose of methotrexate.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Erythema / chemically induced. Foot. Hand. Methotrexate / adverse effects
  • [MeSH-minor] Adult. Carcinoma, Squamous Cell / drug therapy. Drug Eruptions / pathology. Humans. Injections, Intravenous. Male. Mouth Neoplasms / drug therapy. Stomatitis / chemically induced. Stomatitis / pathology

  • MedlinePlus Health Information. consumer health - Foot Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17179620.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


15. Blumenschein GR Jr, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M: Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol; 2009 Sep 10;27(26):4274-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
  • We evaluated the antitumor response and tolerability of sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer (NSCLC), most of whom had received prior platinum-based chemotherapy.
  • Patients with relapsed or refractory advanced NSCLC received sorafenib 400 mg orally twice daily until tumor progression or an unacceptable drug-related toxicity occurred.
  • The predominant histologies were adenocarcinoma (54%) and squamous cell carcinoma (31%).
  • Four patients with SD developed tumor cavitation.
  • Major grades 3 to 4, treatment-related toxicities included hand-foot skin reaction (10%), hypertension (4%), fatigue (2%), and diarrhea (2%).
  • Nine patients died within a 30-day period after discontinuing sorafenib, and one patient experienced pulmonary hemorrhage that was considered drug related.
  • CONCLUSION Continuous treatment with sorafenib 400 mg twice daily was associated with disease stabilization in patients with advanced NSCLC.
  • The broad activity of sorafenib and its acceptable toxicity profile suggest that additional investigation of sorafenib as therapy for patients with NSCLC is warranted.
  • [MeSH-major] Benzenesulfonates / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Pyridines / therapeutic use
  • [MeSH-minor] Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Diarrhea / chemically induced. Drug Resistance, Neoplasm. Fatigue / chemically induced. Female. Humans. Male. Middle Aged. Nausea / chemically induced. Neoplasm Recurrence, Local. Niacinamide / analogs & derivatives. Phenylurea Compounds. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19652055.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00101413
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


16. Diamantis ML, Chon SY: Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma. J Drugs Dermatol; 2010 Feb;9(2):169-71
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma.
  • Sorafenib is a multikinase inhibitor that blocks tumor cell proliferation and angiogenesis and is used for the treatment of advanced renal cell carcinoma, unresectable hepatocellular carcinoma, and other solid tumors.
  • Various dermatologic side effects have been reported, most notably a hand-foot-skin reaction (HFSR).
  • This is a case of a sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma.
  • This patient also developed cutaneous squamous cell carcinoma and HFSR in association with sorafenib.
  • To the authors' knowledge, a psoriasiform eruption due to sorafenib has not been reported in the literature and has important therapeutic implications.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Benzenesulfonates / adverse effects. Drug Eruptions / etiology. Protein Kinase Inhibitors / adverse effects. Psoriasis / chemically induced. Pyridines / adverse effects. Thyroid Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20214183.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


17. Shinoda M, Ogino A, Ozaki N, Urano H, Hironaka K, Yasui M, Sugiura Y: Involvement of TRPV1 in nociceptive behavior in a rat model of cancer pain. J Pain; 2008 Aug;9(8):687-99
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the mechanisms underlying cancer pain, we developed a rat model of cancer pain by inoculating SCC-158 into the rat hind paw, resulting in squamous cell carcinoma, and determined the time course of thermal, mechanical sensitivity, and spontaneous nocifensive behavior in this model.
  • In addition, pharmacological and immunohistochemical studies were performed to examine the role played by transient receptor potential vanilloid (TRPV)1 and TRPV2 expressed in the dorsal root ganglia.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Nociceptors / physiopathology. Pain / etiology. TRPV Cation Channels / physiology
  • [MeSH-minor] Analgesics, Opioid / administration & dosage. Analgesics, Opioid / pharmacology. Animals. Behavior, Animal / drug effects. Behavior, Animal / physiology. Capsaicin / administration & dosage. Capsaicin / analogs & derivatives. Capsaicin / pharmacology. Cell Line, Tumor. Foot Diseases / complications. Foot Diseases / metabolism. Foot Diseases / pathology. Ganglia, Spinal / drug effects. Ganglia, Spinal / metabolism. Ganglia, Spinal / pathology. Hyperalgesia / drug therapy. Hyperalgesia / etiology. Hyperalgesia / physiopathology. Immunohistochemistry. Injections, Intraperitoneal. Injections, Subcutaneous. Male. Morphine / administration & dosage. Morphine / pharmacology. Neoplasms, Experimental / complications. Neoplasms, Experimental / metabolism. Neoplasms, Experimental / pathology. Pain Measurement / methods. Pain Threshold. Rats. Rats, Inbred F344. Ruthenium Red / administration & dosage. Ruthenium Red / pharmacology

  • MedlinePlus Health Information. consumer health - Pain.
  • Hazardous Substances Data Bank. CAPSAICIN .
  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18455478.001).
  • [ISSN] 1528-8447
  • [Journal-full-title] The journal of pain : official journal of the American Pain Society
  • [ISO-abbreviation] J Pain
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / TRPV Cation Channels; 0 / Trpv1 protein, rat; 11103-72-3 / Ruthenium Red; 76I7G6D29C / Morphine; LFW48MY844 / capsazepine; S07O44R1ZM / Capsaicin
  •  go-up   go-down


18. Cabebe E, Wakelee H: Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol; 2007 Feb;8(1):15-27
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OPINION STATEMENT: Successful inhibition of angiogenesis with the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab has improved the efficacy seen with standard cytotoxic therapy in NSCLC.
  • The addition of bevacizumab to first-line chemotherapy improved response rate and progression free survival and added 2 months to median overall survival for those patients with advanced stage NSCLC on the treatment arm of E4599.
  • Unfortunately about half of all patients are not eligible either because they have squamous histology, brain metastases, or are on anti-coagulation.
  • The largest class of drugs that block angiogenesis are the multi-targeted tyrosine kinase inhibitors (TKIs) that target the VEGF receptor (VEGFR).
  • These drugs are still in development, and though two are now on the market for treating other malignancies, their role in NSCLC is under investigation.
  • Rash, fatigue, myalgia, and hand-foot syndrome are more specifically seen with TKIs.
  • These compounds may also be synergistic or additive with traditional cytotoxic chemotherapy drugs and other novel compounds.
  • In early trials sorafenib as a single agent has shown no clinical response in previously treated NSCLC patients, whereas clinical benefit in combination with erlotinib or chemotherapy has been seen in early studies.
  • Vandetanib has demonstrated objective responses as a single agent and in combination with chemotherapy in previously treated NSCLC patients.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Enzyme Inhibitors / therapeutic use. Lung Neoplasms / drug therapy. Vascular Endothelial Growth Factor Receptor-1 / antagonists & inhibitors
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Bevacizumab. Clinical Trials as Topic. Humans. Indoles / therapeutic use. Neovascularization, Pathologic. Niacinamide / analogs & derivatives. Phenylurea Compounds. Piperidines / therapeutic use. Pyridines / therapeutic use. Pyrroles / therapeutic use. Quinazolines / therapeutic use. Signal Transduction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 2004 Feb;53(2):133-40 [14593497.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):25-35 [16314617.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] Br J Cancer. 1997;75(4):477-81 [9052396.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8715-21 [16951187.001]
  • [Cites] Trends Cell Biol. 1996 Dec;6(12):454-6 [15157501.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1546-56 [12684431.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4743-50 [17909199.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Jan;49(1):69-77 [11855754.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2184-91 [15169807.001]
  • [Cites] Ann Oncol. 2005 Aug;16(8):1391-7 [15905307.001]
  • [Cites] Ann Surg. 1972 Mar;175(3):409-16 [5077799.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7462-9 [16103100.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1871-8 [18398152.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(2):139-55 [8534863.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4593-9 [9377574.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6997-7000 [12460918.001]
  • [Cites] Mol Cancer Ther. 2003 Oct;2(10 ):1011-21 [14578466.001]
  • [Cites] Clin Lung Cancer. 2005 Sep;7(2):89-91 [16179094.001]
  • [Cites] Cell. 1991 Jan 25;64(2):327-36 [1703045.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Trends Pharmacol Sci. 1998 Jun;19(6):216-22 [9666712.001]
  • [Cites] Trends Biochem Sci. 2003 Sep;28(9):488-94 [13678960.001]
  • [Cites] Cancer Metastasis Rev. 1993 Sep;12(3-4):303-24 [8281615.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(14):2386-93 [9059326.001]
  • [Cites] J Cell Sci. 2001 Mar;114(Pt 5):853-65 [11181169.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5474-83 [16027439.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] J Biol Chem. 2004 Oct 29;279(44):45556-63 [15322124.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4092-9 [16943527.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] Trends Pharmacol Sci. 1995 Feb;16(2):57-66 [7539171.001]
  • [Cites] J Clin Oncol. 2009 May 20;27(15):2523-9 [19332730.001]
  • [Cites] FASEB J. 1999 Jan;13(1):9-22 [9872925.001]
  • [Cites] Hum Pathol. 1995 Jan;26(1):86-91 [7821921.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4389-400 [15899831.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5597-602 [12359773.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4368-80 [12409337.001]
  • (PMID = 17634832.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Enzyme Inhibitors; 0 / Indoles; 0 / Phenylurea Compounds; 0 / Piperidines; 0 / Pyridines; 0 / Pyrroles; 0 / Quinazolines; 25X51I8RD4 / Niacinamide; 2S9ZZM9Q9V / Bevacizumab; 9ZOQ3TZI87 / sorafenib; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; V99T50803M / sunitinib; YO460OQ37K / N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine
  • [Number-of-references] 59
  •  go-up   go-down


19. Lorenzen S, Duyster J, Lersch C, von Delius S, Hennig M, Bredenkamp R, Peschel C, Lordick F: Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. Br J Cancer; 2005 Jun 20;92(12):2129-33
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In all, 24 patients with advanced disease (17 squamous cell carcinoma and seven adenocarcinoma) received oral capecitabine (1000 mg m(-2) twice daily on days 1-14) plus intravenous docetaxel (75 mg m(-2) on day 1) every 3 weeks as first- (n = 16) or second-line (n = 8) therapy.
  • Patients received a median of four cycles of treatment (range, 0-6).
  • Of the 11 responders (one complete and 10 partial), nine of 16 (56%) received first-line and two of eight (25%) received second-line therapy.
  • The median time to progression was 6.1 months (95% confidence interval (CI), 4.5-7.7 months).
  • Severe adverse events (grade 3/4) reported were: neutropenia (42%, including febrile neutropenia 8%), hand-foot syndrome (29%), diarrhoea (13%), sensory neuropathy (13%), anaemia (8%) and fatigue (8%).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Administration Schedule. Feasibility Studies. Female. Fluorouracil / analogs & derivatives. Humans. Male. Middle Aged. Survival Analysis. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2812-23 [12065558.001]
  • [Cites] Invest New Drugs. 2002 Feb;20(1):95-9 [12003198.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1735-43 [14630678.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1190-7 [15026800.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):955-9 [15151954.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Jpn J Clin Oncol. 1992 Jun;22(3):172-6 [1518165.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):164-70 [8558192.001]
  • [Cites] Med Oncol. 1996 Jun;13(2):87-93 [9013471.001]
  • [Cites] Eur J Cancer. 1997 Jul;33(8):1216-20 [9301445.001]
  • [Cites] Clin Cancer Res. 1998 Apr;4(4):1013-9 [9563897.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1826-34 [9586897.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):485-93 [10080589.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3270-5 [10506629.001]
  • [Cites] J Chronic Dis. 1961 Apr;13:346-53 [13704181.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 15):12-20 [10566606.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1337-45 [10715306.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;45(4):291-7 [10755317.001]
  • [Cites] Invest New Drugs. 2000 Nov;18(4):343-54 [11081570.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2282-92 [11304782.001]
  • [Cites] J Clin Oncol. 2001 Nov 1;19(21):4097-106 [11689577.001]
  • [Cites] Jpn J Clin Oncol. 2001 Sep;31(9):419-23 [11689594.001]
  • [Cites] Br J Cancer. 2003 Aug 18;89(4):630-3 [12915869.001]
  • (PMID = 15942631.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2361804
  •  go-up   go-down


20. Pivot X, Chamorey E, Guardiola E, Magné N, Thyss A, Otto J, Giroux B, Mouri Z, Schneider M, Milano G: Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients. Ann Oncol; 2003 Oct;14(10):1578-86
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The combination of cisplatin and 5-fluorouracil (5-FU) is considered to be the standard treatment in induction chemotherapy for patients with squamous cell carcinoma of the head and neck.
  • Capecitabine (Xeloda) is an oral fluoropyrimidine that is preferentially activated at the tumoral level, exploiting the higher thymidine phosphorylase activity in tumoral tissue.
  • This phase I trial was conducted in patients with locally recurrent or metastatic head and neck carcinoma.
  • The treatment plan included cisplatin on day 1 every 21 days, followed by capecitabine twice daily from day 2 to day 15, with a 1-week rest period.
  • Pharmacokinetic investigations concerned plasma measurement of unchanged capecitabine, 5'-deoxy-5-fluorocytidine, 5'-doxifluridine and 5-FU using an optimized high performance liquid chromatography method, and cisplatin measurement in plasma using a limited sampling procedure.
  • Dose-limiting toxicities occurring during the first cycle (grade >/= 3) were observed on level 2 (one patient with diarrhea, nausea, vomiting, hand-foot syndrome, one toxic death due to renal failure and neutropenia, one patient with neutropenia) and on level 3 (one patient with diarrhea, one patient with hand-foot syndrome and one patient with neutrothrombocytopenia).
  • There was no evidence of pharmacokinetic-pharmacodynamic relationships with the drugs and metabolites investigated.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14504061.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


21. Ishihara K, Saida T, Otsuka F, Yamazaki N, Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society: Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int J Clin Oncol; 2008 Feb;13(1):33-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update.
  • BACKGROUND: In the previous report of the Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society, we tabulated data on patients with malignant melanoma who had been registered at major medical institutions (22 institutions on average) in Japan over 5-year periods from 1987 to 1991 (group A) and from 1992 to 1996 (group B).
  • In addition, the numbers of patients with various kinds of skin malignancies, including not only malignant melanoma but also basal cell carcinoma, squamous cell carcinoma, mycosis fungoides, actinic keratosis, Bowen's disease, and Paget's disease, registered at approximately 100 medical institutions in Japan from 1987 to 2001, were also investigated and data were tabulated.
  • RESULTS: The nationwide survey of Japanese patients with malignant skin tumors from 1987 to 2001 showed that the most prevalent skin tumor was basal cell carcinoma, which increased year by year, followed by squamous cell carcinoma, and then by malignant melanoma.
  • The following results were obtained from the data for melanoma patients registered at major institutions from 1987 to 2001. (1) The overall 10-year survival rates for melanoma patients in each chronological group were ranked as: group C > B > A, although only the difference between groups C and A was statistically significant. (2) The male-to-female ratio ranged from 1: 0.97 to 1: 1.14, and the survival rate of female patients was higher than that of male patients (the 140-month survival rate was 70.6% in females and 60% in males). (3) Assessment of the age distribution showed that the number of patients increased rapidly from ages 40-49 years and reached a peak at around 60 years in all three groups. (4) The sole of the foot was the most common site of melanoma in both males and females, while melanomas on the lower limbs were also prevalent in females. (5) Acral lentiginous melanoma (ALM) was the most common type in all three groups, accounting for nearly 50% of the patients in each group.
  • The number of patients with superficial spreading melanoma (SSM) increased steadily over time and exceeded the number of patients with nodular melanoma (NM) in group C.
  • In group C, the overall survival rate of stage IV patients with a normal serum lactic dehydrogenase (LDH) level was higher than that of patients with elevated LDH values. (9) Evaluation of the effects of some therapeutic procedures (prophylactic lymph node dissection and chemotherapy with and without interferon-beta) on the survivals of patients with melanoma was inconclusive and suggested the need for more studies in this area.
  • CONCLUSION: In Japan, the number of patients with malignant skin tumors has increased year by year.
  • [MeSH-major] Melanoma / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Epidemiol. 1995 Oct;24(5):897-907 [8557445.001]
  • [Cites] Int J Clin Oncol. 2003 Jun;8(3):139-50 [12851837.001]
  • [Cites] Int J Clin Oncol. 2001 Jun;6(3):109-16 [11706778.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1484-91 [10717634.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3635-48 [11504745.001]
  • [Cites] Harefuah. 1995 Jun 15;128(12):745-51, 824 [7557679.001]
  • (PMID = 18307017.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


22. Miyamoto S, Maeda Y, Hishima T, Sasaki T: [Case of higher efficacy by chemoradiotherapy for anal canal cancer from left cervix metastases to lymph nodes]. Gan To Kagaku Ryoho; 2009 Feb;36(2):329-32
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biopsy showed a squamous cell carcinoma.
  • She was searched from head to foot, but the primary carcinoma could not be identified.
  • It was referred to our hospital as a primary unidentified carcinoma.
  • In examination, the anal region had phyma in a rectal examination, and biopsy revealed it to be a squamous cell carcinoma.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / blood. Colonoscopy. Female. Humans. Lymphatic Metastasis / pathology. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223758.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


23. Tsai JY, Iannitti D, Berkenblit A, Akerman P, Nadeem A, Rathore R, Harrington D, Roye D, Miner T, Barnett JM, Maia C, Stuart K, Safran H: Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer. Am J Clin Oncol; 2005 Aug;28(4):329-33
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: A phase I trial was conducted to determine the maximally tolerated dose (MTD) and dose-limiting toxicities (DLTs) of docetaxel, capecitabine, and carboplatin for first-line treatment of patients with metastatic esophageal and gastric cancers.
  • RESULTS: There were no DLTs in the first cycle of treatment.
  • Dose reductions were required in 10 of 15 patients at the final dose level due to neutropenia, nausea, vomiting, diarrhea, dehydration, and hand/foot syndrome following a median of 3 cycles of treatment.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Esophageal Neoplasms / drug therapy. Esophagogastric Junction. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Area Under Curve. Capecitabine. Carboplatin / administration & dosage. Carboplatin / pharmacokinetics. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / analogs & derivatives. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Maximum Tolerated Dose. Middle Aged. Nausea / chemically induced. Neutropenia / chemically induced. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16062072.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 6804DJ8Z9U / Capecitabine; BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Ishihara K, Saida T, Yamamoto A, Japanese Skin Cancer Society Prognosis and Statistical Investigation Committee: Updated statistical data for malignant melanoma in Japan. Int J Clin Oncol; 2001 Jun;6(3):109-16
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A statistical investigation was conducted of Japanese melanoma patients who had been registered by the Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society.
  • METHODS: The data analyzed included age, sex, anatomical distribution, clinical features of primary lesions, Clark's subtype, tumor thickness, Clark's level, disease stage, and treatment.
  • In addition, the results of a nationwide survey of various types of skin malignancies, obtained from 101 medical institutions in Japan between 1987 and 1996, were analyzed.
  • It is noteworthy that the numbers of actinic keratoses, a type of early squamous cell carcinoma in situ, showed a steep increase in recent years.
  • (1) the male-to-female ratio was 1 to 1.06, (2) the survival rate of female patients was higher than that of male patients (10-year survival in group B: female, 71.6% vs male, 55.9%), (3) the commonest site of melanoma in both sexes was the sole of the foot, (4) with respect to Clark's subtype, acral lentiginous melanoma was commonest, accounting for about half of all melanomas, (5) nodular melanoma showed the worst prognosis among the subtypes, (6) patients in stage IIIB and stage IV had an unfavorable outcome, with 10-year survivals of less than 50% and less than 10%, respectively, (7) Clark's level of invasion, as well as Breslow's tumor thickness of the primary lesions, were confirmed to be important prognostic factors, and (8) prophylactic lymph node dissection in stage II and IIIA and chemotherapy in stage IV seemed to have limited effect on the prognosis.
  • CONCLUSION: The prognosis of advanced melanoma is poor, as it is highly resistant to chemotherapy.
  • Thus, to improve the prognosis, early detection is mandatory, and this is possible because this neoplasm appears as a distinctive pigmented lesion on the skin.
  • [MeSH-major] Melanoma / epidemiology. Neoplasm Staging. Registries. Skin Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Japan / epidemiology. Lymph Node Excision. Male. Middle Aged. Neoplasm Invasiveness. Prevalence. Prognosis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11706778.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


25. Ichioka S, Ohura N, Nakatsuka T: The positive experience of using a growth factor product on deep wounds with exposed bone. J Wound Care; 2005 Mar;14(3):105-9
MedlinePlus Health Information. consumer health - Wounds and Injuries.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study investigates whether it can facilitate closure in wounds with deep soft-tissue defects and exposed bone, where surgical closure is not possible.
  • [MeSH-major] Fibroblast Growth Factors / administration & dosage. Peptide Fragments / administration & dosage. Wound Healing / drug effects. Wounds and Injuries / drug therapy
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Bone and Bones. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / surgery. Diabetic Foot / complications. Eyelid Neoplasms / complications. Eyelid Neoplasms / surgery. Female. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15779638.001).
  • [ISSN] 0969-0700
  • [Journal-full-title] Journal of wound care
  • [ISO-abbreviation] J Wound Care
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Peptide Fragments; 131094-16-1 / trafermin; 62031-54-3 / Fibroblast Growth Factors
  •  go-up   go-down






Advertisement